<DOC>
	<DOCNO>NCT00144677</DOCNO>
	<brief_summary>The purpose study evaluate ability sirolimus prevent graft versus host disease ( GVHD ) patient follow stem cell transplant unrelated donor . This trial design test hypothesis elimination methotrexate unrelated donor group would lead less transplant-related toxicity still preserve effective control GVHD .</brief_summary>
	<brief_title>Sirolimus With Tacrolimus Graft-vs-Host Disease Prophylaxis After Un-Related Stem Cell Transplantation</brief_title>
	<detailed_description>- Therapy prevent GVHD consist infusion tacrolimus intravenously sirolimus orally daily start 3 day stem cell infusion . This take place hospital patient remain duration transplant . - Sirolimus continue approximately 100 day stable dose , tapered slowly course week month prevent flare GVHD . - Patients see clinic weekly first 2 month discharge hospital . If GVHD present , taper schedule slow base patient 's clinical condition . - Tacrolimus also give orally patient discharge tapered schedule sirolimus . - During year follow stem cell transplant , blood test perform evaluate immune system graft versus host disease .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Acute myelogenous leukemia ( AML ) first subsequent remission , untreated first relapse treat relapse . Acute lymphoblastic leukemia ( ALL ) first subsequent remission , untreated first relapse treat relapse . Chronic myelogenous leukemia first second chronic stable phase accelerate phase . Myelodysplastic syndrome myeloproliferative disease NonHodgkin 's lymphoma Hodgkin 's disease second great complete remission , partial remission , induction failure . Chronic lymphocytic leukemia , Rai stage 24 , progress initial therapy . Matched unrelated donor . Age 1855 year time stem cell transplantation ECOG performance status 02 Life expectancy 100 day without stem cell transplantation Total bilirubin &lt; 2.0 mg/dl AST &lt; 90 IU Serum creatinine &lt; 2.0 mg/dl Ejection fraction &gt; 40 % echocardiogram gate nuclear medicine study . Uncontrolled infection Forced vital capacity DLCO &lt; 50 % predict age Uncontrolled hypertension Prior hematopoietic stem cell transplant Evidence HIV infection active Hepatitis B C infection Cholesterol &gt; 300 mg/dl Relapsed aggressive Burkitt 's Burkitt'slike lymphoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>Graft versus Host Disease</keyword>
	<keyword>GVHD</keyword>
	<keyword>sirolimus</keyword>
	<keyword>tacrolimus</keyword>
	<keyword>Stem cell transplant</keyword>
</DOC>